Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07122453

Safety and PK of Intrathecal CNTX-3001 for Intractable Chronic Low Back Pain

This clinical study is being conducted to evaluate the safety, tolerability, plasma pharmacokinetics and efficacy of an investigational drug called CNTX-3001. This Phase 1 study is the first time that CNTX-3001 will be given to people (first-in-human study). The study is being done to evaluate whether CNTX-3001, given into the intrathecal space by lumbar puncture, can be administered safely to participants who have been diagnosed with intractable chronic moderate to severe low back pain and who have not responded well to other treatments in the past.

CNTX-3001 is a novel, non-opioid small molecule

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion:

  • Have stable intractable, chronic moderate to severe low back pain
  • Must have failed all 3 of the following categories of therapies:
  • Physical medicine modalities for at least 6 weeks (e.g., physical therapy, occupational therapy, or chiropractic treatment directed at chronic low back pain)
  • Three or more classes of pharmacologic treatments
  • One or more non-surgical and/or surgical interventions addressing the primary cause of chronic low back pain
  • If the intractable low back pain is accompanied by radicular pain, back pain must be dominant over leg pain and may not radiate below the knee
  • Has normal leg strength in both legs (able to stand/walk)
  • Willing and able to undergo the lumbar puncture
  • On a stable analgesic regimen, or a stable dose of an opioid medication for >3 months
  • Non- or ex-smoker and has not used any nicotine-containing products within 3 months
  • Men or women able to abide by reproductive and contraceptive requirements
  • Has a body mass index (BMI) between 18 and 35 kg/m2, with weight ≥60 kg

Exclusion

  • Substantial increase or decrease in pain over the prior 3 months.
  • Low back pain that only occurs with specific activities or body positions.
  • Has asthma or other severe respiratory disease requiring daily prescription medication
  • History of, or current cancer (except basal cell carcinoma), cardiac disease, immunological disorders, meningitis, or bleeding disorders
  • Confirmed diagnosis of fibromyalgia or myalgic encephalomyelitis

Exclusion

  • Substantial increase or decrease in pain over the prior 3 months
  • Low back pain that only occurs with specific activities or body positions
  • Has asthma or other severe respiratory disease requiring daily prescription medication
  • History of, or current cancer (except basal cell carcinoma), cardiac disease, immunological disorders, meningitis, or bleeding disorders
  • Confirmed diagnosis of fibromyalgia or myalgic encephalomyelitis

Treatment and study plan

CNTX-3001

Drug

non-opioid analgesic

Placebo

Drug

Placebo product

Primary outcomes

  1. Incidence of treatment emergent adverse events

    Time frame: From baseline to the end of treatment visit (Day 7)

    Number of participants with TEAEs, which includes laboratory test variables

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of CNTX-3001

    Time frame: Pre dose to up to 4 hours post dose

  2. Time to Maximum Observed Plasma Concentration (Tmax) of CNTX-3001

    Time frame: Pre dose to up to 4 hours post dose

  3. Area Under the Concentration-time Curve up to the Last Measurable Concentration of CNTX-3001

    Time frame: Pre dose to up to 4 hours post dose

Study contacts

Contact information is provided by the study sponsor or research team.

Clinical Operations

CONTACT

[email protected]

(617) 837-6911

Sponsors and collaborators

Lead sponsor

Centrexion Therapeutics

Industry

Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

Registry information

Official study title

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Single Ascending Doses of Intrathecal CNTX-3001 in Subjects With Intractable Chronic Moderate to Severe Low Back Pain

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Aug 14, 2025
Registry last updated
Mar 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.